New claims:

1. Use of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific tumor and, due to the treatment with lipopolysaccaride (LPS) and interferon-gamma (IFN-γ), release IL-12, for the preparation of a medicament for treating a patient having said specific tumor.

2. Use according to claim 1, characterised in that said treatments is performed after bone marrow transplantation.

3. Use according to claim 1 or 2, characterised in that said specific tumor is an advanced malignancy.

4. Use according to any one of claims 1 to 3, characterised in that in said DCs are DCs having been taken from the patient having said specific tumor or from the bone marrow donor.

5. Use according to any one of claims 1 to 4, characterised in that the DCs have been loaded with an antigen from a tumor cell from said patient having said specific tumor.

6. Use according to any one of claims 1 to 5, characterised in that the DCs are additionally charged with a tracer antigen.

7. Use according to claim 6, characterised in that said tracer antigen is keyhole limpet hemocyanine (KLH).

8. Use according to any one of claims 1 to 7, characterised in that the DCs are additionally charged with an adjuvant, especially with tetanus toxoid.

9. Use according to any one of claims 1 to 8, characterised in that the DCs have been generated in vitro from peripheral blood mononuclear cells (PBMCs).

10. Composition for triggering IL-12 release from DCs containing LPS, IFN-γ and a tumor antigen.

11. Composition according to claim 10, characterised in that it

is calf-serum free.

12. Use of a combination of LPS, IFN-γ and a tumor antigen for triggering IL-12 release from DCs.

13. Use according to claim 12, characterised in that the DCs have been loaded with an antigen from a tumor cell from a patient having said tumor.

14. Kit for triggering IL-12 release from DCs comprising
- LPS,
- IFN-γ and
- a tumor antigen.

15. Use of a kit according to claim 14 for triggering IL-12 release from DCs.

16. Use according to claim 15, characterised in that the DCs have been loaded with an antigen from a tumor cell from a patient having said tumor.